ETNK2 (ethanolamine kinase 2) encodes an enzyme that specifically catalyzes the phosphorylation of ethanolamine, functioning in the phosphatidylethanolamine biosynthetic pathway without choline kinase activity 1. The enzyme localizes to the cytoplasm and cytosol where it participates in phospholipid metabolism 1. ETNK2 demonstrates significant disease relevance across multiple cancer types. In gastric cancer, elevated ETNK2 expression is associated with hepatic metastasis and poor prognosis, potentially through dysregulation of the p53-Bcl-2 intrinsic apoptosis pathway 2. Conversely, in renal cell carcinoma, low ETNK2 expression correlates with poor prognosis and immunosuppressive tumor microenvironment 3. The gene shows enhanced expression in lung cancer tissue, supporting elevated phosphatidylethanolamine turnover compared to normal tissue 1. ETNK2 has been identified as a dengue virus host factor, with knockdown reducing viral infection in hepatocyte cell lines 4. Additionally, promoter hypermethylation of ETNK2 contributes to radioresistance in laryngeal cancer cells 5. The gene participates in epistatic interactions affecting cardiovascular-related protein levels and is subject to chr1 insulator regulation 67. These findings establish ETNK2 as a metabolically important gene with complex roles in cancer progression and treatment resistance.